Analyzing...
Loading company...
Nothing flagged for monitoring
“Services business in Healthcare — Hospitals & Diagnostics.”
₹1,111 Cr service revenue.
Employee costs at 4.5% of revenue — primary cost driver.
“By 2930, we are working for revenue of 6,000 crores, 4,000 in Retailer and around 2,000 in B2C. This will generate around 4 to 5% EBITDA”
“I'm targeting the last quarter of next year. So in '26 last quarter, it would be able to close at 500 crore”
“Targeting 4,000 crore number in Whitivar Shakti by FY30”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 3.8%▼ | 7.9% |
| ROCE | 0.9%▼ | 11.3% |
| Net Margin | 2.0%▼ | 9.3% |
| EBITDA Margin | 1.1%▼ | 21.9% |
| Debt To Equity | 0.00x▼ | 0.16x |
| Rev Growth 3yr | 22.1%▲ | 12.4% |
| Employee Cost Ratio | 4.50x | - |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| ₹1,231 Cr +10.8% | ₹1,111 Cr -19.2% | ₹1,376 Cr +32.3% | ₹1,040 Cr +64.7% | ₹631 Cr +15.2% | ₹548 Cr +42.2% | ₹385 Cr +76.4% | ₹219 Cr | |
| ₹66 Cr +10.5% | ₹60 Cr -0.9% | ₹60 Cr +155.6% | ₹24 Cr +103.2% | ₹12 Cr +239.3% | ₹3 Cr +9.9% | ₹3 Cr +29.3% | ₹2 Cr | |
| Total Income | ₹1,297 Cr +10.8% | ₹1,171 Cr -18.5% | ₹1,436 Cr +35.0% | ₹1,063 Cr +65.4% | ₹643 Cr +16.6% | ₹552 Cr +42.0% | ₹389 Cr +75.9% | ₹221 Cr |
| COGS | ₹1,123 Cr +10.4% | ₹1,017 Cr -17.5% | ₹1,233 Cr +28.4% | ₹960 Cr +64.9% | ₹582 Cr +18.3% | ₹492 Cr +34.2% | ₹367 Cr +83.9% | ₹199 Cr |
| ₹1,290 Cr +10.0% | ₹1,173 Cr -15.0% | ₹1,380 Cr +26.3% | ₹1,093 Cr +59.3% | ₹686 Cr +20.8% | ₹568 Cr +27.2% | ₹446 Cr +69.3% | ₹264 Cr | |
| Profit Before Tax | ₹8 Cr ↑ Recovery | (₹193 Cr) ↓ Decline | ₹56 Cr ↑ Recovery | (₹37 Cr) ↓ Decline | ₹1,115 Cr ↑ Recovery | (₹16 Cr) +71.6% | (₹58 Cr) -34.9% | (₹43 Cr) |
| Exceptional Items | ₹0.11 Cr ↑ Recovery | (₹191 Cr) | ₹0.00 Cr +100.0% | (₹8 Cr) ↓ Decline | ₹1,157 Cr | ₹0.00 Cr -100.0% | ₹0.29 Cr | ₹0.00 Cr |
| (₹21 Cr) +69.7% | (₹70 Cr) -92.9% | (₹36 Cr) -59.6% | (₹23 Cr) ↓ Decline | ₹131 Cr | ₹0.73 Cr ↑ Recovery | (₹5 Cr) ↓ Decline | ₹1.00 Cr | |
| Net Profit | ₹29 Cr ↑ Recovery | (₹134 Cr) ↓ Decline | ₹6 Cr ↑ Recovery | (₹99 Cr) ↓ Decline | ₹978 Cr ↑ Recovery | (₹17 Cr) +67.2% | (₹52 Cr) -19.3% | (₹44 Cr) |
| Profit (Owners) | ₹26 Cr ↑ Recovery | (₹91 Cr) ↓ Decline | ₹9 Cr ↑ Recovery | (₹72 Cr) ↓ Decline | ₹709 Cr ↑ Recovery | (₹10 Cr) +73.2% | (₹39 Cr) -1.1% | (₹38 Cr) |
| Minority Interest | ₹3 Cr ↑ Recovery | (₹42 Cr) | (₹3 Cr) +88.9% | (₹27 Cr) ↓ Decline | ₹270 Cr ↑ Recovery | (₹7 Cr) +49.8% | (₹13 Cr) -150.3% | (₹5 Cr) |
| Other Comprehensive Income | (₹0.01 Cr) +98.5% | (₹0.45 Cr) ↓ Decline | ₹0.12 Cr ↑ Recovery | (₹1 Cr) -365.1% | (₹0.26 Cr) ↓ Decline | ₹0.25 Cr ↑ Recovery | (₹0.24 Cr) | ₹0.00 Cr |
| EPS | ₹8.19 | (₹28.66) | ₹2.79 | (₹22.70) | ₹222.73 | (₹3.27) | (₹12.20) | (₹12.06) |
| Diluted Shares | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
| Profit Or Loss Of Associates | ₹0.00 Cr +100.0% | (₹11 Cr) +87.5% | (₹86 Cr) -1.5% | (₹85 Cr) | (₹5 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Health X Platform Limited has informed the Exchange about Link of Recording
Health X Platform Limited has informed the Exchange about Intimation for change of website of the Company
BANWARI LAL MITTAL has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations...
Health X Platform Limited has informed the Exchange about Copy of Newspaper Publication
Health X Platform Limited has informed the Exchange about Intimation under Regulation 30 of SEBI (LODR) Reg, 2015 Completion of the transfer of the entire equity stake of Mitsubishi Corporation held...
Sastasundar Ventures Limited has informed the Exchange about General Updates on approval received from Stock Exchanges for Change in Name and Symbol
Sastasundar Ventures Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Sastasundar Ventures Limited has informed the Exchange about Schedule of meet
Sastasundar Ventures Limited has informed the Exchange about Schedule of meet
Sastasundar Ventures Limited has informed the Exchange regarding Disclosure under Regulation 30 of SEBI (LODR) - Outcome of Board Meeting held on February 27, 2026.
Sastasundar Ventures Limited has informed the Exchange about disclosure under Reg 30 of SEBI (LODR) - Intimation by Sastasundar Healthbuddy Limited, material subsidiary of the Company, regarding Outco...
Sastasundar Ventures Limited has informed the Exchange regarding Outcome of Board Meeting held on February 26, 2026 regarding in-principle approval of Scheme of Arrangement by the Board of Directors o...
Sastasundar Ventures Limited has informed the Exchange that the name of the Company has been changed from Sastasundar Ventures Limited to Health X Platform Limited
Sastasundar Ventures Limited has informed the Exchange about Transcript of the Earnings Conference call for Q3 FY 26.
Sastasundar Ventures Limited has informed the Exchange about Update on the Reduction of Share Capital of Genu Path Labs Limited, step-down subsidiary of the Company
No dividend history available for this company.